HEOR

News

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

Six digital cardiac rehabilitation programmes can be used by the NHS in England, but more data is needed on seven others, says NICE.

News

NICE backs NHS use of an AstraZeneca drug for one rare disease, but says it can't recommend a BioMarin therapy for another.

News

Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.

News

More details have emerged of a UK plan for new medicines to get simultaneous decisions from the MHRA and NICE on their use by the NHS.